The biotech industry underestimated how a new political administration would impact the mRNA space. The change in leadership led to significant regulatory uncertainty and a general risk aversion towards mRNA technology, which in turn suppressed faith and funding despite the platform's recent successes.

While the current influx of biotech IPOs is a positive sign for the industry, historical data shows that excessive IPO activity often coincides with tops in major biotech indices like the XBI. This is a counterintuitive risk for investors to monitor.

The recent biotech market upswing isn't just a reaction to broader economic shifts. It's fundamentally supported by greater clarity on drug pricing, successful commercial launches by biotech firms, and a strong M&A environment, indicating robust industry health.

While massive, oversubscribed follow-on financings for companies with positive data indicate renewed investor appetite, the true market recovery hinges on the IPO window reopening. Analysts remain deeply divided on whether 2026 will see a significant number of IPOs, suggesting a fragile recovery.

The recent rally in some biotech stocks is likely just the beginning. Key indicators of a full-blown bull market, such as a resurgence in biotech IPOs and a rally in large tool companies (e.g., Thermo Fisher), have not yet occurred, suggesting the cycle is still in its early innings.

The reopening of the biotech IPO market is fragile. A key risk identified by investors is a series of failed IPOs, which could halt the sector's positive momentum. Consequently, there is intense pressure on bankers and VCs to exhibit "quality discipline," ensuring that only the most mature and high-potential companies go public first to build a track record of success.

A significant disconnect exists in biotech funding. Public markets show strong recovery with over $7B in follow-on financing this quarter, while private venture financing has dropped to its lowest point since 2017. This suggests a lag effect, where public investor confidence is returning faster than private capital deployment.

The biotech industry is entering a paradoxical period. Financial markets show signs of recovery with rising follow-ons and potential IPOs, suggesting a bear market end. However, this optimism is contrasted by significant uncertainty and political turmoil at key US agencies like the FDA and NIH, creating a challenging operating environment for innovation.

The past few years in biotech mirrored the tech dot-com bust, driven by fading post-COVID exuberance, interest rate hikes, and slower-than-hoped commercialization of new modalities like gene editing. This was caused by a confluence of factors, creating a tough environment for companies that raised capital during the peak.